Background The United States (US) Expanded Access Program (EAP) to coronavirus disease 2019 (COVID-19) convalescent plasma was initiated in response to the rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19. While randomized clinical trials were in various stages of development and enrollment, there was an urgent need for widespread access to potential therapeutic agents. The objective of this study is to report on the demographic, geographical, and chronological characteristics of patients in the EAP, and key safety metrics following transfusion of COVID-19 convalescent plasma. Methods and findings Mayo Clinic served as the central institutional review board for all participating facilities, and any US physician could participate as a local physician–principal investigator. Eligible patients were hospitalized, were aged 18 years or older, and had—or were at risk of progression to—severe or life-threatening COVID-19; eligible patients were enrolled through the EAP central website. Blood collection facilities rapidly implemented programs to collect convalescent plasma for hospitalized patients with COVID-19. Demographic and clinical characteristics of all enrolled patients in the EAP were summarized. Temporal patterns in access to COVID-19 convalescent plasma were investigated by comparing daily and weekly changes in EAP enrollment in response to changes in infection rate at the state level. Geographical analyses on access to convalescent plasma included assessing EAP enrollment in all national hospital referral regions, as well as assessing enrollment in metropolitan areas and less populated areas that did not have access to COVID-19 clinical trials. From April 3 to August 23, 2020, 105,717 hospitalized patients with severe or life-threatening COVID-19 were enrolled in the EAP. The majority of patients were 60 years of age or older (57.8%), were male (58.4%), and had overweight or obesity (83.8%). There was substantial inclusion of minorities and underserved populations: 46.4% of patients were of a race other than white, and 37.2% of patients were of Hispanic ethnicity. Chronologically and geographically, increases in the number of both enrollments and transfusions in the EAP closely followed confirmed infections across all 50 states. Nearly all national hospital referral regions enrolled and transfused patients in the EAP, including both in metropolitan and in less populated areas. The incidence of serious adverse events was objectively low (<1%), and the overall crude 30-day mortality rate was 25.2% (95% CI, 25.0% to 25.5%). This registry study was limited by the observational and pragmatic study design that did not include a control or comparator group; thus, the data should not be used to infer definitive treatment effects. Conclusions These results suggest that the EAP provided widespread access to COVID-19 convalescent plasma in all 50 states, including for underserved racial and ethnic minority populations. The study design of the EAP may serve as a model for future efforts when broad access to a treatment is needed in response to an emerging infectious disease. Trial registration ClinicalTrials.gov NCT#: NCT04338360 . In an observational study of registry data, Jonathon Senefeld and colleagues study factors related to patient enrollment in the Expanded Access Program for use of COVID-19 convalescent plasma in the United States. Author summary Why was this study done? There was a public health need to provide expedited and broad access to convalescent plasma for the treatment of coronavirus disease 2019 (COVID-19) during the early stages of this public health emergency in the United States. Convalescent plasma was initially administered through regulatory pathways that required per-patient approval, resulting in substantial administrative time. The Expanded Access Program (EAP) was initiated to provide broad access to COVID-19 convalescent plasma and to provide a framework for standardized collection of data describing the safety profile of convalescent plasma. What did the researchers do and find? The EAP provided rapid and broad access to convalescent plasma throughout the US and some US territories and was effective at providing therapy for demographic groups that were severely affected by COVID-19. In addition, the data provide evidence supporting that transfusion of convalescent plasma is safe in hospitalized patients with COVID-19. What do these findings mean? The study design of the EAP may serve as an example for future efforts in response to a rapidly developing infectious disease when broad access to a treatment is needed in areas and demographic groups that are often poorly represented in clinical trials.
【초록키워드】 COVID-19, Treatment, coronavirus disease, convalescent plasma, public health, SARS-CoV-2, randomized clinical trial, Coronavirus disease 2019, coronavirus, therapy, Hospitalized, Clinical characteristics, obesity, hospital, Infection, clinical trials, risk, Local, Infectious disease, progression, hospitalized patients, severe acute respiratory syndrome Coronavirus, observational study, Expanded access, Spread, Region, male, Patient, Study design, Emerging infectious disease, plasma, age, mortality rate, public health emergency, infection rate, United States, incidence, transfusion, respiratory, demographic, early stage, safety profile, COVID-19 convalescent plasma, Evidence, Pragmatic, framework, overweight, Safe, causative agent, institutional review board, Metrics, Racial, Serious Adverse Events, Serious Adverse Event, acute respiratory syndrome, Older, Factor, Enrollment, Mayo Clinic, Trial registration, 95% CI, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, Eligible patients, website, potential therapeutic agents, Stage, early stages, effort, life-threatening, approval, investigator, treatment effects, demographic and clinical characteristics, National, Hispanic ethnicity, blood collection, regulatory pathways, while, regulatory pathway, demographic groups, central institutional review board, Expanded Access Program, registry data, researcher, Administered, Inclusion, The United States, regions, widespread, populations, effective, 30-day mortality rate, enrolled, resulting, affected, example, include, United State, addition, investigated, required, provided, majority, less, changes in, hospitalized patient, analysis, initiated, Temporal, increases in, characteristics of patient, demographic group, eligible patient, transfused, with COVID-19, 【제목키워드】 COVID-19, access, National, the United State,